Involvement of cochlin binding to sulfated heparan sulfate/heparin in the pathophysiology of autosomal dominant late-onset hearing loss (DFNA9).
Tomoko HondaNorihito KawasakiRei YanagiharaRyo TamuraKarin MurakamiTomomi IchimiyaNaoki MatsumotoShoko NishiharaKazuo YamamotoPublished in: PloS one (2022)
Late-onset non-syndromic autosomal dominant hearing loss 9 (DFNA9) is a hearing impairment caused by mutations in the coagulation factor C homology gene (COCH). COCH encodes for cochlin, a major component of the cochlear extracellular matrix. Though biochemical and genetic studies have characterized the properties of wild-type and mutated cochlins derived from DFNA9, little is known about the underlying pathogenic mechanism. In this study, we established a cochlin reporter cell, which allowed us to monitor the interaction of cochlin with its ligand(s) by means of a β-galactosidase assay. We found a class of highly sulfated glycosaminoglycans (GAGs), heparin, that were selectively bound to cochlin. The interaction was distinctly abrogated by N-desulfation, but not by 2-O- or 6-O-desulfation. The binding of cochlin to GAG was diminished by all of the point mutations found in DFNA9 patients. Through GAG composition analysis and immunostaining using mouse cochlin/immunoglobulin-Fc fusion protein, we identified moderately sulfated GAGs in mouse cochlea tissue; this implies that cochlin binds to such sulfated GAGs in the cochlea. Since GAGs play an important role in cell growth and survival as co-receptors of signal transduction mechanisms, the interaction of cochlin with GAGs in the extracellular matrix could aid the pathological research of autosomal dominant late-onset hearing loss in DFNA9.
Keyphrases
- late onset
- hearing loss
- extracellular matrix
- early onset
- wild type
- end stage renal disease
- chronic kidney disease
- genome wide
- newly diagnosed
- high throughput
- stem cells
- single cell
- growth factor
- dna methylation
- crispr cas
- cell therapy
- autism spectrum disorder
- dna binding
- binding protein
- transcription factor
- patient reported outcomes